eccogene glp-1 BioWorld eccogene glp-1 Oral Small-Molecule GLP-1

All data were normalized to GAPDH and are expressed as fold increase from the 24- to 38-year-old control group (1-way ANOVA with Tukeys multiple-comparison test)

Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease

Tsiami AP, Goulis DG, Sotiriadis AI, Kolibianakis EM

This pinpoints an anti-obesity mechanism via epitranscriptomic control

reported that cleavage products derived from GLP-1 reduced tubulointerstitial renal damage, lowered the expression of tubular injury markers, and attenuated the renal accumulation of macrophages and T cells (Moellmann et al., 2018)